PLL Therapeutics to present ALS research strategy at Bioshares Biotech Summit
Ella Day | August 7, 2025 | News story | Medical Communications, Research and Development | Bioshares Biotech Summit, Neurology, PLL Therapeutics, amyotrophic lateral sclerosis, neurodegenerative diseases
French biotech, PLL Therapeutics, will present its approach to early detection and treatment of Amyotrophic Lateral Sclerosis (ALS) at the Bioshares Biotech Summit in Hobart, Australia. The presentation forms part of the summit’s “What the Heck Biotech!” session, focusing on novel therapeutic strategies.
PLL Therapeutics is currently progressing a phase 1 clinical trial in ALS. The study recently completed its initial safety phase, involving 12 patients who received three different doses of the company’s candidate PLL001 or placebo via subcutaneous injection. Following safety validation, the trial will proceed to phase 2, which aims to enrol 140 participants beginning in September this year.
At the summit, CEO Jean-Pascal Zambaux will discuss the company’s polypeptide delivery platform and the role of gut integrity in ALS pathogenesis. The platform is based on poly-L-Lysine, which is being investigated for its potential to target inflammation, restore the gut lining and blood-brain barrier, and reduce neuroinflammatory triggers suspected to contribute to ALS progression.
The company is also exploring early-stage biomarkers for ALS. Within the current trial, large-scale blood sampling is underway to assess a diagnostic kit designed to measure biomarkers linked to gut permeability. These biomarkers may assist in detecting disease onset and tracking response to treatment.
PLL001 is based on a delivery system that administers small chain fatty acids to the gut and brain, with the aim of reducing neuroinflammation.
Ella Day
7/8/25
Related Content
Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …
Neurizon confirms positive results for prospective ALS treatment
Neurizon Therapeutics has announced new preclinical data confirming that NUZ-001 and its active metabolite, NUZ-001 …
Corcept reports survival benefit in ALS trial of dazucorilant despite missing primary endpoint
Corcept Therapeutics has announced results from its phase 2 DAZALS study investigating dazucorilant in patients …
